The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery
| Status: | Completed |
|---|---|
| Conditions: | Arthritis, Osteoarthritis (OA) |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 20 - 90 |
| Updated: | 10/19/2013 |
| Start Date: | September 2010 |
| End Date: | September 2012 |
| Contact: | Mark P Figgie, M.D |
| Email: | figgiem@hss.edu |
| Phone: | 212-606-1932 |
Application of "Evicel" hemostatic matrix during operation for unilateral total knee
replacement surgery (TKA) will result in decreased bleeding and postoperative drain output,
a reduction in transfusion requirements, and less reduction of hemoglobin.
No additional data desired
Inclusion Criteria:
- Diagnosis of degenerative joint disease of the knee in patients medically suitable to
undergo unilateral TKA.
- Age range 20-90
Exclusion Criteria:
- Known allergies to human blood products.
- History of bleeding disorders.
- Younger than 20, older than 90
- Patients with previous arthrotomy, however, with exception of medial or lateral
menisectomy.
- Patients taking Lovenox, Plavix, Aggrenox or erythropoetin. (coumadin is acceptable)
- Additionally, any patient with an intra-operative complication (i.e bone fracture,
vascular injury) or post-operative complication that would affect bleeding tendency
will be excluded although data will be recorded for later analysis. Also, any patient
who has a complication with the suction drain (eg inadvertently being pulled out,
suction failing) will have the remaining data points recorded and drain measurements
will be excluded from analysis.
We found this trial at
1
site
Hospital for Special Surgery Founded in 1863, Hospital for Special Surgery is the nation
Click here to add this to my saved trials
